Daiichi Sankyo’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
You may also be interested in...
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
Bristol/Pfizer’s Eliquis secures an attractive FDA label for atrial fibrillation on three key fronts: superior stroke prevention, reduced major bleeding and reduced all-cause mortality. With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety. But Boehringer’s competing Pradaxa remains the only new oral anticoagulant with proven superiority for preventing purely ischemic strokes, which is the main goal of atrial fibrillation treatment.
Xarelto Takes Lead In Exploiting VTE Market Opportunity
J&J/Bayer’s Xarelto currently has the broadest label among new anticoagulants, with a new indication in the U.S. for venous thromboembolism. But Bristol/Pfizer’s Eliquis is also being positioned for broader use in VTE, with positive data reported at the American Society of Hematology meeting in December.
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
Boehringer Ingelheim GmbH's breakthrough anticoagulant Pradaxa (dabigatran) will be available to physicians and patients in the "next several days," the company said after FDA cleared the drug Oct. 19.